TUDORZA PRESSAIR
LAMA DPI
Aclidinium bromide · AstraZeneca (Circassia)
Active Medication & Mechanism
- Aclidinium bromide LAMA400 mcg per actuation (delivers 375 mcg from mouthpiece)
Long-acting muscarinic antagonist. Blocks M3 muscarinic receptors on airway smooth muscle, reducing cholinergic bronchoconstriction. Rapidly hydrolyzed in plasma, reducing systemic anticholinergic effects.
FDA-Approved Dosing by Indication
// approval varies by strength + age COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 400 mcg | Adults (≥18 years) | 1 inhalation twice daily (morning and evening) Long-term maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. | 800 mcg | FDA Approved |
Asthma
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | All patients | — | — | Not Approved Tudorza Pressair is NOT indicated for asthma. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute bronchospasm. Use a SABA. |